• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

OXCARBAZEPINE Drug Record

  • Summary
  • Interactions
  • Claims
  • OXCARBAZEPINE chembl:CHEMBL1068 Approved

    Alternate Names:

    SPN-804
    GP-47680
    KIN-493
    OXTELLAR XR
    OXCARBAZEPINE
    TRILEPTAL
    TRI476
    OCBZ
    10,11-DIHYDRO-10-OXO-5H-DIBENZ(B,F)AZEPINE-5-CARBOXAMIDE
    chemidplus:28721-07-5
    rxcui:32624
    chembl:CHEMBL1068
    drugbank:00776
    pubchem.compound:34312

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications anticonvulsant
    Drug Class anticonvulsants
    Year of Approval 2000
    (4 More Sources)

    Publications:

    Vohora et al., 2010, Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs., Drugs Today
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Lu Y et al., 2017, Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy., Eur J Clin Pharmacol
    Ma CL et al., 2014, Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy., Pharmacogenomics
    Kwan P et al., 2008, Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression., Pharmacogenet Genomics
    Rädisch S et al., 2014, A comprehensive functional and clinical analysis of ABCC2 and its impact on treatment response to carbamazepine., Pharmacogenomics J
    Sporis D et al., 2013, Lack of association between polymorphism in ABCC2 gene and response to antiepileptic drug treatment in Croatian patients with epilepsy., Coll Antropol
    Qu J et al., 2012, ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients., CNS Neurosci Ther
    Hilger E et al., 2012, Lack of association between ABCC2 gene variants and treatment response in epilepsy., Pharmacogenomics
    Hung CC et al., 2012, Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization., Pharmacogenomics
    Ufer M et al., 2011, Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy., Pharmacogenet Genomics
    Kwan P et al., 2011, Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy., Pharmacogenomics
    Shen C et al., 2017, Effects of ABCB1, ABCC2, UGT2B7 and HNF4α genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy., Seizure
    Ma CL et al., 2015, SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy., Pharmacogenomics
    Moon J et al., 2016, HLA-B*40:02 and DRB1*04:03 are risk factors for oxcarbazepine-induced maculopapular eruption., Epilepsia
    Bertok S et al., 2017, The association of SCN1A p.Thr1067Ala polymorphism with epilepsy risk and the response to antiepileptic drugs in Slovenian children and adolescents with epilepsy., Seizure
    Daci A et al., 2015, Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients., PLoS One
    Haerian BS et al., 2013, SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis., Pharmacogenomics
    Zhou BT et al., 2012, Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up., CNS Neurosci Ther
    Kumari R et al., 2011, Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population., Indian J Hum Genet
    Shorvon S, 2000, Oxcarbazepine: a review., Seizure
    Schmidt D et al., 2000, Oxcarbazepine for Treatment of Partial Epilepsy: A Review and Recommendations for Clinical Use., Epilepsy Behav
    Thomas AM et al., 2018, Old Friends With New Faces: Are Sodium Channel Blockers the Future of Adjunct Pain Medication Management?, J Pain
  • OXCARBAZEPINE   UGT1A7

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27900402


    Sources:
    PharmGKB

  • OXCARBAZEPINE   UGT1A10

    Interaction Score: 0.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27900402


    Sources:
    PharmGKB

  • OXCARBAZEPINE   SCN1A

    Interaction Score: 0.57

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    28753467 26555147 25155934 23859570 22591328 21747585 10845729 12737829 28842369


    Sources:
    ChemblInteractions PharmGKB

  • OXCARBAZEPINE   UGT1A8

    Interaction Score: 0.56

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27900402


    Sources:
    PharmGKB

  • OXCARBAZEPINE   ABCC2

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25155934 24567120 23697249 22630058 22256867 22188362 21799461 21449672


    Sources:
    PharmGKB

  • OXCARBAZEPINE   UGT2B7

    Interaction Score: 0.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28837897 25823783


    Sources:
    PharmGKB

  • OXCARBAZEPINE   UGT1A9

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27900402


    Sources:
    PharmGKB

  • OXCARBAZEPINE   SCN5A

    Interaction Score: 0.22

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Novel drug target Established target

    PMIDs:
    20502724 17016423 17139284


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • OXCARBAZEPINE   SCN2A

    Interaction Score: 0.21

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    25155934 18784617


    Sources:
    ChemblInteractions PharmGKB

  • OXCARBAZEPINE   HLA-DRB1

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27666425


    Sources:
    PharmGKB

  • OXCARBAZEPINE   HLA-B

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • OXCARBAZEPINE   SCN11A

    Interaction Score: 0.1

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • OXCARBAZEPINE   SCN7A

    Interaction Score: 0.06

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • OXCARBAZEPINE   SCN8A

    Interaction Score: 0.06

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • OXCARBAZEPINE   SCN3A

    Interaction Score: 0.05

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • OXCARBAZEPINE   SCN4A

    Interaction Score: 0.05

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • OXCARBAZEPINE   SCN9A

    Interaction Score: 0.05

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Sodium channel alpha subunit blocker

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • OXCARBAZEPINE   SCN10A

    Interaction Score: 0.04

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • OXCARBAZEPINE   ABCB1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28837897


    Sources:
    PharmGKB

  • OXCARBAZEPINE   VDR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: OXCARBAZEPINE

    • Version: 01-August-2011

    Alternate Names:
    OXCARBAZEPINE Primary Drug Name

    Drug Info:
    Year of Approval 2000
    Drug Class anticonvulsants

    Publications:

  • TdgClinicalTrial: OXCARBAZEPINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications anticonvulsant
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: oxcarbazepine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Moon J et al., 2016, HLA-B*40:02 and DRB1*04:03 are risk factors for oxcarbazepine-induced maculopapular eruption., Epilepsia
    Kwan P et al., 2011, Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy., Pharmacogenomics
    Qu J et al., 2012, ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients., CNS Neurosci Ther

  • DTC: OXCARBAZEPINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1068 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Oxcarbazepine

    • Version: 2020.06.01

    Alternate Names:
    D0QL3P TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1068

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1068

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Oxcarbazepine

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21